HC Wainwright Issues Negative Forecast for Eyenovia Earnings

Eyenovia, Inc. (NASDAQ:EYEN) – Analysts at HC Wainwright decreased their FY2024 earnings estimates for Eyenovia in a research note issued to investors on Monday, November 18th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.52) per share for the year, down from their previous estimate of ($0.51). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.10) EPS, FY2025 earnings at ($0.46) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.16) EPS and FY2028 earnings at $0.05 EPS.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter in the previous year, the company posted ($0.18) earnings per share.

A number of other research analysts also recently commented on EYEN. William Blair reissued a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th. Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH restated a “neutral” rating on shares of Eyenovia in a research note on Monday.

Eyenovia Price Performance

Shares of NASDAQ EYEN opened at $0.12 on Wednesday. The business has a 50-day moving average of $0.47 and a 200-day moving average of $0.70. Eyenovia has a fifty-two week low of $0.09 and a fifty-two week high of $2.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $7.64 million, a price-to-earnings ratio of -0.16 and a beta of 1.75.

Insiders Place Their Bets

In other news, CEO Michael M. Rowe purchased 50,000 shares of Eyenovia stock in a transaction that occurred on Monday, August 26th. The shares were acquired at an average price of $0.57 per share, for a total transaction of $28,500.00. Following the transaction, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. The trade was a 151.85 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 7.10% of the company’s stock.

Institutional Trading of Eyenovia

Several large investors have recently bought and sold shares of EYEN. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eyenovia during the 2nd quarter valued at approximately $26,000. Ground Swell Capital LLC bought a new position in Eyenovia in the 2nd quarter valued at approximately $27,000. Nations Financial Group Inc. IA ADV boosted its position in Eyenovia by 24.4% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the period. Financial Management Network Inc. bought a new stake in Eyenovia during the 3rd quarter worth approximately $39,000. Finally, SkyView Investment Advisors LLC acquired a new position in Eyenovia in the 2nd quarter valued at approximately $87,000. 25.84% of the stock is owned by institutional investors and hedge funds.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.